Efficacy and safety of TNX-102 SL (sublingual cyclobenzaprine) for the treatment of fibromyalgia: results from the randomized, placebo-controlled RELIEF trial

Annie Iserson,Lesley Arnold,Ben Vaughn,Mary Kelley,Gregory Sullivan

Arthritis care & research（2023）

引用 0|浏览2

暂无评分

摘要

In this phase 3, randomized, controlled trial of patients with fibromyalgia, treatment with TNX-102 SL was associated with significant reductions in daily pain and was safe and well tolerated.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要